Abstract
Heparin is a glycosaminoglycan mixture currently used in prophylaxis and treatment of thrombosis. Heparin possesses non-anticoagulant properties, including modulation of various proteases, interactions with fibroblast growth factors, and anti-inflammatory actions. Senile dementia of Alzheimer’s type is accompanied by inflammatory responses contributing to irreversible changes in neuronal viability and brain function. Vascular factors are also involved in the pathogenesis of senile dementia. Inflammation, endogenous proteoglycans, and assembly of senile plagues and neurofibrillary tangles contribute directly and indirectly to further neuronal damage. Neuron salvage can be achieved by antiinflammation and the competitive inhibition of proteoglycans accumulation. The complexity of the pathology of senile dementia provides numerous potential targets for therapeutic interventions designed to modulate inflammation and proteoglycan assembly. Heparin and related oligosaccharides are known to exhibit anti-inflammatory effects as well as inhibitory effects on proteoglycan assembly and may prove useful as neuroprotective agents.
Keywords: pentasaccharide sequence, fibroblast growth factors, non-anticoagulant actions, serine protease inhibitors, tissue factor pathway inhibitor
Current Pharmaceutical Design
Title: Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Volume: 13 Issue: 15
Author(s): Qing Ma, Umberto Cornelli, Israel Hanin, Walter P. Jeske, Robert J. Linhardt, Jeanine M. Walenga, Jawed Fareed and John M. Lee
Affiliation:
Keywords: pentasaccharide sequence, fibroblast growth factors, non-anticoagulant actions, serine protease inhibitors, tissue factor pathway inhibitor
Abstract: Heparin is a glycosaminoglycan mixture currently used in prophylaxis and treatment of thrombosis. Heparin possesses non-anticoagulant properties, including modulation of various proteases, interactions with fibroblast growth factors, and anti-inflammatory actions. Senile dementia of Alzheimer’s type is accompanied by inflammatory responses contributing to irreversible changes in neuronal viability and brain function. Vascular factors are also involved in the pathogenesis of senile dementia. Inflammation, endogenous proteoglycans, and assembly of senile plagues and neurofibrillary tangles contribute directly and indirectly to further neuronal damage. Neuron salvage can be achieved by antiinflammation and the competitive inhibition of proteoglycans accumulation. The complexity of the pathology of senile dementia provides numerous potential targets for therapeutic interventions designed to modulate inflammation and proteoglycan assembly. Heparin and related oligosaccharides are known to exhibit anti-inflammatory effects as well as inhibitory effects on proteoglycan assembly and may prove useful as neuroprotective agents.
Export Options
About this article
Cite this article as:
Ma Qing, Cornelli Umberto, Hanin Israel, Jeske P. Walter, Linhardt J. Robert, Walenga M. Jeanine, Fareed Jawed and Lee M. John, Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia, Current Pharmaceutical Design 2007; 13 (15) . https://dx.doi.org/10.2174/138161207780765918
DOI https://dx.doi.org/10.2174/138161207780765918 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery Pharmacological Overview and Future Perspectives of Cholinergic Therapy in Alzheimers Disease
Current Drug Therapy Ca2+ Signalling in Damaged Endothelium: Do Connexin Hemichannels Aid in Filling the Gap?
Current Drug Therapy The Role of Phosphorylation in Synucleinopathies: Focus on Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery
Current Neuropharmacology Formulation and In Vitro Evaluation of Gelatin Nanospheres for the Oral Delivery of Selegiline
Current Nanoscience Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Hybrid Therapy in the Management of Atrial Fibrillation
Current Cardiology Reviews Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry The Role of Anionic Peptide Fragments in 1N4R Human Tau Protein Aggregation
Protein & Peptide Letters The Effects of Different Antioxidants on the Activity of Cerebrocortical MnSOD and Na,K-ATPase from post mortem Alzheimer’s Disease and Age-matched Normal Brains
Current Alzheimer Research Sepsis in the Central Nervous System and Antioxidant Strategies with Nacetylcysteine, Vitamins and Statins
Current Neurovascular Research Editorial [Hot Topic: Drug Targets in Alzheimers Disease (Executive Editors: G. Munch and G. Stuchbury)]
Current Pharmaceutical Design Editorial (Thematic Issue: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and Development: Clinical Implications)
CNS & Neurological Disorders - Drug Targets Association Study of IL-4 -590 C/T and DDX39B -22 G/C Polymorphisms with the Risk of Late-Onset Alzheimer’s Disease in Iranian Population
Current Aging Science Differential Susceptibility of Naive and Differentiated PC-12 Cells to Methylglyoxal-Induced Apoptosis: Influence of Cellular Redox
Current Neurovascular Research Cystatin C: An Emerging Biomarker in Cardiovascular Disease
Current Topics in Medicinal Chemistry Coffee: A Rich Source of Antimicrobial and Antiviral Compounds
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) The Role of P-glycoprotein in Cerebral Amyloid Angiopathy; Implications for the Early Pathogenesis of Alzheimers Disease
Current Alzheimer Research